Ultragenyx Pharmaceutical (RARE) Property, Plant & Equipment (Net) Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -14.40% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.41% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -9.89% |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 13.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.71% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -0.31% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -4.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.90% |
| Dec 31, 2025 | -2.06% |
| Sep 30, 2025 | 2.13% |
| Jun 30, 2025 | 7.24% |
| Mar 31, 2025 | 13.79% |
| Dec 31, 2024 | 23.49% |
| Sep 30, 2024 | 31.77% |
| Jun 30, 2024 | 38.65% |
| Mar 31, 2024 | 48.21% |
| Dec 31, 2023 | 58.11% |
| Sep 30, 2023 | 82.57% |
| Mar 31, 2023 | 80.06% |
| Dec 31, 2022 | 80.25% |
| Sep 30, 2022 | 94.52% |
| Jun 30, 2022 | 101.58% |
| Mar 31, 2022 | 101.34% |
| Dec 31, 2021 | 91.71% |
| Sep 30, 2021 | 81.76% |
| Jun 30, 2021 | 71.15% |
| Mar 31, 2021 | 61.39% |
| Dec 31, 2020 | 49.87% |
| Sep 30, 2020 | 44.90% |
| Mar 31, 2020 | 42.30% |
| Dec 31, 2019 | 37.51% |
| Sep 30, 2019 | 20.48% |
| Jun 30, 2019 | 14.08% |
| Mar 31, 2019 | 17.37% |
| Dec 31, 2018 | 39.57% |
| Sep 30, 2018 | 46.66% |
| Jun 30, 2018 | 63.50% |
| Mar 31, 2018 | 80.98% |
| Dec 31, 2017 | 93.10% |
| Sep 30, 2017 | 82.88% |
| Jun 30, 2017 | 87.29% |
| Mar 31, 2017 | 110.26% |
| Dec 31, 2016 | 134.36% |